Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin with Closed Loop Control in Adolescents with Diabetic Nephropathy
NCT06115460Phase 3Completed
- Sponsor
- Ain Shams University
- Start
- Mar 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sitagliptin in type 1 diabetes mellitus (T1D) and diabetic nephropathy (DN) (2 arms), sponsored by Ain Shams University. Primary endpoint: Percentage of Time in range at 3 months. Started Mar 2022; status: completed.
02
Drugs
sitagliptin
03
Conditions
type 1 diabetes mellitus (T1D)diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT06115460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06115460.